Literature DB >> 17405794

Use of pure bicarbonate-buffered peritoneal dialysis fluid reduces the incidence of CAPD peritonitis.

Jesús Montenegro1, Ramón Saracho, Isabel Gallardo, Isabel Martínez, Rosa Muñoz, Nuria Quintanilla.   

Abstract

BACKGROUND: Advances in bag connection technology have reduced the incidence of peritonitis in CAPD patients but there is little information on the effect of the new peritoneal dialysis fluids.
METHODS: We studied the incidence of CAPD peritonitis for about 3 years in 100 incident patients--50 patients dialysed with lactate-buffered solution, pH 5.5 and containing glucose degradation products (GDP) (lactate group), and 50 patients with pure bicarbonate-buffered solution, pH 7.4 and low GDP (bicarbonate group). Patients in both groups were similar in age, sex, length of time on CAPD, connection technology and handling of dialysis.
RESULTS: In the lactate group, 74 episodes of peritonitis were recorded compared with 43 in the bicarbonate group, i.e. one episode per 21 patient-months with the lactate dialysis fluid and one episode per 36 patient-months with the bicarbonate dialysis fluid (OR 0.58, 95% CI 0.37-0.91, P = 0.017). A total of 3369 exchanges per episode of peritonitis were recorded for bicarbonate compared with 2004 exchanges per episode of peritonitis in the lactate group. The majority of organisms isolated in both groups were Gram-positive bacteria, with a predominance of the oropharyngeal and cutaneous endogenous flora. Three episodes of fungal peritonitis occurred in the lactate group and none in the bicarbonate group.
CONCLUSIONS: Our results suggest that the pure bicarbonate-buffered peritoneal dialysis fluid appears to reduce the frequency of peritonitis in CAPD patients possibly in relation to greater biocompatibility and maintenance of peritoneal membrane structural integrity. Similar results can probably relate to all low-GDP solutions.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17405794     DOI: 10.1093/ndt/gfl848

Source DB:  PubMed          Journal:  Nephrol Dial Transplant        ISSN: 0931-0509            Impact factor:   5.992


  19 in total

1.  Peritonitis in the patient on peritoneal dialysis: does the composition of the dialysis fluid make a difference?

Authors:  Danica Lam; Joanne M Bargman
Journal:  Clin J Am Soc Nephrol       Date:  2013-08-15       Impact factor: 8.237

2.  Our war against bacteria in peritoneal dialysis, the last 40 years!

Authors:  Dimitrios G Oreopoulos; Antonios H Tzamaloukas
Journal:  Int Urol Nephrol       Date:  2008       Impact factor: 2.370

3.  The promising future of long-term peritoneal dialysis.

Authors:  Dimitrios Oreopoulos; Elias Thodis; Kosmas I Paraskevas
Journal:  Int Urol Nephrol       Date:  2008       Impact factor: 2.370

4.  Effects of biocompatible versus standard fluid on peritoneal dialysis outcomes.

Authors:  David W Johnson; Fiona G Brown; Margaret Clarke; Neil Boudville; Tony J Elias; Marjorie W Y Foo; Bernard Jones; Hemant Kulkarni; Robyn Langham; Dwarakanathan Ranganathan; John Schollum; Michael Suranyi; Seng H Tan; David Voss
Journal:  J Am Soc Nephrol       Date:  2012-03-22       Impact factor: 10.121

5.  Solutions for peritoneal dialysis in children: recommendations by the European Pediatric Dialysis Working Group.

Authors:  Claus Peter Schmitt; Sevcan A Bakkaloglu; Günter Klaus; Cornelis Schröder; Michel Fischbach
Journal:  Pediatr Nephrol       Date:  2011-03-31       Impact factor: 3.714

Review 6.  An update on peritoneal dialysis solutions.

Authors:  Elvia García-López; Bengt Lindholm; Simon Davies
Journal:  Nat Rev Nephrol       Date:  2012-02-21       Impact factor: 28.314

7.  The effects of biocompatible compared with standard peritoneal dialysis solutions on peritonitis microbiology, treatment, and outcomes: the balANZ trial.

Authors:  David W Johnson; Fiona G Brown; Margaret Clarke; Neil Boudville; Tony J Elias; Marjorie W Y Foo; Bernard Jones; Hemant Kulkarni; Robyn Langham; Dwarakanathan Ranganathan; John Schollum; Michael G Suranyi; Seng H Tan; David Voss
Journal:  Perit Dial Int       Date:  2012 Sep-Oct       Impact factor: 1.756

8.  Infusion fluids contain harmful glucose degradation products.

Authors:  Anna Bryland; Marcus Broman; Martin Erixon; Bengt Klarin; Torbjörn Lindén; Hans Friberg; Anders Wieslander; Per Kjellstrand; Claudio Ronco; Ola Carlsson; Gabriela Godaly
Journal:  Intensive Care Med       Date:  2010-04-16       Impact factor: 17.440

Review 9.  Pathogenesis and treatment of peritoneal membrane failure.

Authors:  Ramesh Saxena
Journal:  Pediatr Nephrol       Date:  2007-09-21       Impact factor: 3.714

10.  Effect of the dialysis fluid buffer on peritoneal membrane function in children.

Authors:  Claus Peter Schmitt; Barbara Nau; Gita Gemulla; Klaus E Bonzel; Tuula Hölttä; Sara Testa; Michel Fischbach; Ulrike John; Markus J Kemper; Anja Sander; Klaus Arbeiter; Franz Schaefer
Journal:  Clin J Am Soc Nephrol       Date:  2012-11-02       Impact factor: 8.237

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.